TY - JOUR T1 - Can measurements of inflammatory biomarkers be used to spot viral infections? JF - medRxiv DO - 10.1101/2020.10.06.20207860 SP - 2020.10.06.20207860 AU - Anirban Sinha AU - René Lutter AU - Tamara Dekker AU - Barbara Dierdorp AU - Peter J. Sterk AU - Urs Frey AU - Edgar Delgado-Eckert Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/07/2020.10.06.20207860.abstract N2 - Accurate detection of human respiratory viral infections is highly topical. We investigated how strongly inflammatory biomarkers (FeNO, eosinophils, neutrophils, and cytokines in nasal lavage fluid) and lung function parameters change upon rhinovirus-16 infection, in order to explore their potential use for infection detection. To this end, within a longitudinal cohort study, healthy and mildly asthmatic volunteers were experimentally inoculated with rhinovirus-16 and time series of these parameters/biomarkers were systematically recorded and compared between the pre- and post-infection phases of the study, which lasted 2 and 1 month/s, respectively. We found that the parameters’/biomarkers’ ability to discriminate between the infected and the uninfected state varied over the observation time period. Consistently over time, the concentration of cytokines in nasal lavage fluid showed moderate to very good discrimination performance, thereby qualifying for disease progression monitoring. On the other hand, lung function and FeNO, while quickly and non-invasively measurable using cheap portable devices (e.g., at airports), performed poorly.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNTR5426/NL5317Funding StatementThe salary of the first author was sponsored from the European Respiratory Society-Marie Sklodowska Curie actions COFUND RESPIRE 2 fellowships (MCF−7077−2014), from a grant supported by Swiss Lung Foundation (2017_14) and internal funds. Acknowledgments: WAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Committee in Amsterdam University Medical Centre (Protocol No. NL54293.018.15).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe following are available online on medRxiv: Figures S1 through S20 displaying the same information as Figures 2 and 3 in the manuscript, but concerning all the remaining parameters/biomarkers used in this study. Tables T1 through T22 displaying summary statistics of the averages, within each gliding time window, of each parameter/biomarker used in this study. Furthermore, Table T23 displaying symptoms data upon inoculation for each study participant, and a copy of the study questionnaire filled out for each participant at each visit. For every parameter/biomarker, and for each cohort participant, pre-challenge time series of windowed averages can be made available upon email request to the corresponding author. ER -